Cancer immunotherapy has been firmly established as a new milestone for cancer therapy,
with the development of multiple immune cells as therapeutic tools. Natural killer (NK) cells …

Cytokines have pivotal roles in immunity, making them attractive as therapeutics for a variety
of immune-related disorders. However, the widespread clinical use of cytokines has been …

We describe a de novo computational approach for designing proteins that recapitulate the
binding sites of natural cytokines, but are otherwise unrelated in topology or amino acid …

Checkpoint blockade with antibodies specific for cytotoxic T lymphocyte–associated protein
(CTLA)-4 or programmed cell death 1 (PDCD1; also known as PD-1) elicits durable tumor …

Cytokines are a class of potent immunoregulatory proteins that are secreted in response to
various stimuli and act locally to regulate many aspects of human physiology and disease …

Therapies modulating the immune system offer the prospect of treating a wide range of
conditions including infectious diseases, cancer and autoimmunity. Biomaterials can …

The therapeutic potential of recombinant cytokines has been limited by the severe side
effects of systemic administration. We describe a strategy to reduce the dose-limiting …

The three-signal paradigm tries to capture how the innate immune system instructs adaptive
immune responses in three well-defined actions:(1) presentation of antigenic peptides in the …

Cancer immunotherapy is now a powerful clinical reality, with a steady progression of new
drug approvals and a massive pipeline of additional treatments in clinical and preclinical …

While IL-2 can potently activate both NK and T cells, its short in vivo half-life, severe toxicity,
and propensity to amplify Treg cells are major barriers that prevent IL-2 from being widely …